In the context of chronic kidney disease and diabetes, available data comparing SGLT2 inhibitors with standard care, sulphonylureas, DPP-4 inhibitors, or insulin remain inconclusive and are characterized by a degree of uncertainty [148]. This evidence concerns the gene SLC5A2 and diabetes mellitus.